Imidazolidinedione derivatives and use thereof as drugs
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/4166
C07D-233/74
출원번호
US-0473889
(2002-04-08)
우선권정보
JP-0112373 (2001-04-11)
국제출원번호
PCT//JP02/03509
(2003-10-02)
§371/§102 date
20031002
(20031002)
국제공개번호
WO02//08364
(2002-10-24)
발명자
/ 주소
Sakai, Yusuke
Inoue, Jun
출원인 / 주소
Senju Pharmaceutical Co., Ltd.
대리인 / 주소
Wenderoth, Lind &
인용정보
피인용 횟수 :
2인용 특허 :
1
초록▼
The present invention is to provide an imidazolidinedione derivative and oxazolidinedione derivative represented by the following general Formula (I) having the chymase and/or tryptase inhibition activity [wherein R1 and R2 are the same or different, and denote a lower alkyl group or a phenyl group,
The present invention is to provide an imidazolidinedione derivative and oxazolidinedione derivative represented by the following general Formula (I) having the chymase and/or tryptase inhibition activity [wherein R1 and R2 are the same or different, and denote a lower alkyl group or a phenyl group, or R1 and R2 are taken together to form a ring, R3 denotes an optionally substituted naphthyl group or heterocyclic group, A denotes oxygen or NR4 (R4 is hydrogen or optionally substituted lower alkyl group), or NB2R5 (R5 is aryl group, and B2 is carbonyl group or sulfonyl group), and B1 denotes a carbonyl group or a sulfonyl group], or a pharmaceutically acceptable salt thereof.
대표청구항▼
1. A compound represented by the general formula (I): wherein R1 and R2 are the same or different, and denote a lower alkyl group or a phenyl group, or R1 and R2 are taken together to form a ring, R3 denotes an optionally substituted naphthyl group or heterocyclic group, A denotes oxygen or NR4 wher
1. A compound represented by the general formula (I): wherein R1 and R2 are the same or different, and denote a lower alkyl group or a phenyl group, or R1 and R2 are taken together to form a ring, R3 denotes an optionally substituted naphthyl group or heterocyclic group, A denotes oxygen or NR4 wherein R4 is hydrogen or optionally substituted lower alkyl group, or NB2R5 wherein R5 is aryl group, and B2 is carbonyl group or sulfonyl group, and B1 denotes a carbonyl group or a sulfonyl group, or a pharmaceutically acceptable salt thereof. 2. The compound according to claim 1, wherein R1 and R2 are the same or different, and are a lower alkyl group or a phenyl group, R3 is a furyl group or an optionally substituted naphthyl group, and A is oxygen or NR4 wherein R4 is hydrogen or optionally substituted lower alkyl group in the general formula (I), or the pharmaceutically acceptable salt thereof.3. The compound according to claim 1, wherein B1 and B2 are a carbonyl group in the general formula (I), or the pharmaceutically acceptable salt thereof.4. A medicament, which comprises the compound as defined in claim 1, or a pharmaceutically acceptable salt thereof.5. A chymase and/or tryptase inhibiting agent, which comprises the compound as defined in claim 1, or a pharmaceutically acceptable salt thereof.6. The medicament according to claim 4, which is an agent for treating diseases associated with chymase and/or tryptase.7. The medicament according to claim 6, wherein the disease associated with chymase and/or tryptase is allergic, inflammatory or circulatory disease.8. The medicament according to claim 6, wherein the disease associated with chymase is chorioretinopathy, glaucoma, myopia or asthenopia.9. A pharmaceutical composition, which comprises the compound as defined in claim 1, or a pharmaceutically acceptable salt thereof.10. A method of treating a disease associated with chymase and/or tryptase, which comprised administering an effective amount of the compound as defined in claim 1, or a pharmaceutically acceptable salt thereof to a warm-blooded animal, wherein the disease is selected from the group consisting of pancreatitis, ulcerative colitis, Crohn's disease, nephritis, hepatitis, bronchopneumonia, atopy, arthritis, rheumatism, keratoconjunctivitis, iridocyclitis, uveitis, orbital inflammation, vernal catarrh, allergic rhinitis, restenosis after circulatory disease, restenosis after blood vessel disorder due to percutaneous transluminal angioplasty, diabetic or non-diabetic renal disorder, peripheral circulatory disorder, itching associated with inflammatory or allergic disorder, chorioretinopathy, retinitis pigmentosa, macular degeneration, ischemic optic nerve disease, arteriovenous occulusion, diabetic retinopathy, choroidal disease following retinal lesion, glaucoma, myopia, asthenopia, thrombophlebitis, disseminated intravascular coagulation, psoriasis, scleroderma, interstitial pneumonia, pulmonary fibrosis, hepatic cirrhosis, periodontal disease and pterygium.11. A method for manufacturing a chymase and/or tryptase inhibiting agent, which comprised mixing the compound of claim 1 or a pharmaceutically acceptable salt thereof with an excipient, binder, disintegrating agent, lubricant, absorption promoter, buffer, surfactant, solubilizer, preservative, emulsifier, isotonic or pH adjusting agent.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (1)
Adams ; Jr. John B. (Hockessin DE) Geffken Detlef (Hamburg DE DEX) Rayner Dennis R. (Centerville DE), Fungicidal oxazolidinones.
Watkins, Anthony N.; Leighty, Bradley D.; Oglesby, Donald M.; Ingram, JoAnne L.; Schryer, Jacqueline L., Sol-gel based oxidation catalyst and coating system using same.
Watkins, Anthony N.; Leighty, Bradley D.; Oglesby, Donald M.; Patry, JoAnne L.; Schryer, Jacqueline L., Sol-gel based oxidation catalyst and coating system using same.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.